## Jun Ren

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/190750/publications.pdf

Version: 2024-02-01

567281 552781 40 762 15 26 citations h-index g-index papers 1167 47 47 47 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy. Oncolmmunology, 2021, 10, 1976953.	4.6	13
2	Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation. International Journal of Radiation Oncology Biology Physics, 2021, 111, 479-490.	0.8	3
3	Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment. Science Translational Medicine, 2021, 13, eabb6981.	12.4	84
4	Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy. American Journal of Cancer Research, 2021, 11, 1709-1718.	1.4	1
5	Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients. Pain, 2020, 161, 127-134.	4.2	15
6	DC-CIK as a widely applicable cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 601-607.	3.1	28
7	Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites. American Journal of Translational Research (discontinued), 2020, 12, 3940-3952.	0.0	0
8	Infiltration of metastatic lymph nodes with PD-1 T cells is associated with improved disease-free and overall survival in resected N NSCLC. American Journal of Cancer Research, 2020, 10, 4435-4449.	1.4	0
9	Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth. Immunotherapy, 2019, 11, 953-966.	2.0	8
10	Functional CD3+CD8+PD1â^ T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast. Clinical Breast Cancer, 2019, 19, e617-e623.	2.4	8
11	Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. Journal of Thrombosis and Thrombolysis, 2019, 47, 505-511.	2.1	5
12	Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors. International Journal of Hyperthermia, 2019, 36, 74-82.	2.5	21
13	Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS). Clinical and Translational Oncology, 2019, 21, 721-728.	2.4	32
14	Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. Clinical Cancer Research, 2019, 25, 1494-1504.	7.0	45
15	Expression of Lymphocyte-Activation Gene 3 (LAG-3) Immune Checkpoint Receptor Identifies a Tumor-Reactive T Cell Population in the Peripheral Blood of Patients with Colorectal Cancer. Medical Science Monitor, 2019, 25, 3495-3502.	1.1	3
16	Predictive significance of T cell subset changes during exi̇̀¿½vivo generation of adoptive cellular therapy products for the treatment of advanced non‑small cell lung cancer. Oncology Letters, 2019, 18, 5717-5724.	1.8	4
17	Inhibition of <scp>ZERO</scp> â€ <scp>BK</scp> by <scp>PKC</scp> is involved in carbacholâ€induced enhancement of rat colon smooth muscle motility. Neurogastroenterology and Motility, 2018, 30, e13312.	3.0	3
18	Association between variations in the disrupted in schizophrenia 1 gene and schizophrenia: A meta-analysis. Gene, 2018, 651, 94-99.	2.2	12

#	Article	IF	CITATIONS
19	CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. Cancer Chemotherapy and Pharmacology, 2018, 81, 365-372.	2.3	8
20	Circulating CD8 + CD28 â^ suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study. Cytotherapy, 2018, 20, 126-133.	0.7	20
21	Structure-based design of peptides against HER2 with cytotoxicity on colon cancer. Artificial Cells, Nanomedicine and Biotechnology, 2017, 45, 649-654.	2.8	3
22	Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. Oncolmmunology, 2017, 6, e1264563.	4.6	23
23	Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clinical Cancer Research, 2017, 23, 5066-5073.	7.0	62
24	Quantitative proteome analysis of colorectal cancer-related differential proteins. Journal of Cancer Research and Clinical Oncology, 2017, 143, 233-241.	2.5	10
25	Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients. Molecular and Clinical Oncology, 2017, 7, 903-910.	1.0	7
26	MicroRNA miR-590-5p inhibits breast cancer cell stemness and metastasis by targeting SOX2. European Review for Medical and Pharmacological Sciences, 2017, 21, 87-94.	0.7	46
27	Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines. Oncology Reports, 2016, 36, 1243-1250.	2.6	7
28	Interaction between DISC1 and CHL1 in regulation of neurite outgrowth. Brain Research, 2016, 1648, 290-297.	2.2	9
29	Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). Clinical and Translational Oncology, 2016, 18, 82-87.	2.4	34
30	The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa. Scientific Reports, 2015, 5, 16775.	3.3	8
31	Regional Variation in Identified Cancer Care Needs of Earlyâ€Career Oncologists in China, India, and Pakistan. Oncologist, 2015, 20, 532-538.	3.7	12
32	Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies. Oncologist, 2015, 20, 773-779.	3.7	44
33	Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 914-922.	0.6	4
34	Continuous DC-CIK Infusions Restore CD8+Cellular Immunity, Physical Activity and Improve Clinical Efficacy in Advanced Cancer Patients Unresponsive to Conventional Treatments. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2419-2423.	1.2	9
35	Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clinical and Translational Oncology, 2013, 15, 780-788.	2.4	38
36	Elevated level of peripheral CD8+CD28â° T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. Cancer Immunology, Immunotherapy, 2013, 62, 1123-1130.	4.2	54

#	Article	IF	CITATIONS
37	Activation of sonic hedgehog signaling pathway is an independent potential prognosis predictor in human hepatocellular carcinoma patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2012, 24, 323-331.	2.2	34
38	Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1197-1203.	2.5	23
39	DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells. Frontiers in Bioscience - Elite, 2011, E3, 240-249.	1.8	11
40	Decrease of peripheral blood CD8+/CD28-suppressor T cell followed by dentritic cells immunomodulation among metastatic breast cancer patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2010, 22, 310-315.	2.2	0